Show simple item record

dc.contributor.authorGanz, Patricia A
dc.contributor.authorCecchini, Reena S
dc.contributor.authorFehrenbacher, Louis
dc.contributor.authorGeyer, Charles E
dc.contributor.authorRastogi, Priya
dc.contributor.authorCrown, John P
dc.contributor.authorThirlwell, Michael P
dc.contributor.authorEllison, David M
dc.contributor.authorBoileau, Jean-Francois
dc.contributor.authorFlynn, Patrick J
dc.contributor.authorJeong, Jong-Hyeon
dc.contributor.authorMamounas, Eleftherios P
dc.contributor.authorWolmark, Norman
dc.date.accessioned2022-02-14T16:53:44Z
dc.date.available2022-02-14T16:53:44Z
dc.date.issued2021-05-20
dc.identifier.issn2374-4677
dc.identifier.pmid34016989
dc.identifier.doi10.1038/s41523-021-00264-2
dc.identifier.urihttp://hdl.handle.net/10147/631465
dc.descriptionThe NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were assessed at entry, 3, 6, 12, 18, 24, 30, and 36 months. Consenting women had estradiol and FSH measurement at entry, 3, 6, 12, 18, and 24 months. Logistic regression determined predictors of amenorrhea and hormone levels at 12, 24, and 36 months. Between 2/8/2011 and 2/10/2015, 3270 women with node-positive/high-risk node-negative HER2-low breast cancer were enrolled. There were 1,458 women enrolled in the MH study; 1231 consented to baseline blood samples. Trastuzumab did not contribute to a higher amenorrhea rate. Amenorrhea predictors were consistent with earlier studies; however, to our knowledge, this is the largest prospective study to include serial reproductive hormone measurements to 24 months and clinical amenorrhea reports to 36 months. These data can help to counsel patients regarding premature menopause risk.en_US
dc.language.isoenen_US
dc.subjectONCOLOGYen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectMENSTRUATIONen_US
dc.titleNRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.en_US
dc.typeArticleen_US
dc.identifier.journalNPJ breast canceren_US
dc.source.journaltitleNPJ breast cancer
dc.source.volume7
dc.source.issue1
dc.source.beginpage55
dc.source.endpage
refterms.dateFOA2022-02-14T16:53:45Z
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
s41523-021-00264-2.pdf
Size:
715.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record